Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2015-01-09 Board/Management Inform…
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 8, 2015, by Tokai Pharmaceuticals, Inc. The key content is the election of Stephen Buckley, Jr. to the Board of Directors, including details about his background, compensation, and indemnification agreement. The document focuses on changes in the company's board and management, specifically the appointment of a new director and related arrangements. There are no financial statements or earnings data, no audit information, no voting results, no merger or acquisition details, and no other report types mentioned. The primary subject is the change in board composition and officer election, which fits the category of Board/Management Information (MANG). The document length is 5868 characters, which is sufficient to contain substantive information rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2015-01-09 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock incentive plans and employee stock purchase plans. It includes details about the securities to be registered, calculation of registration fees, indemnification provisions, and references to other filings. This type of filing is related to share issuance and capital changes, specifically for employee stock plans. It is not an annual report, earnings release, or any other financial report but a registration statement for securities issuance. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the registration statement itself, not just an announcement or certification.
2014-11-20 English
10-Q
Interim / Quarterly Report 9M 2014
2014-11-13 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 10, 2014, reporting the company's financial results for the quarter ended September 30, 2014. It specifically states that the full text of the press release announcing the financial results is furnished as Exhibit 99.1 and incorporated by reference. The document itself is short (2910 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights, not a full interim report or annual report. The presence of a press release as an exhibit further supports this classification.
2014-11-10 English
SC 13G
Major Shareholding Notification
2014-10-22 English
FORM 4 SUBMISSION
Director's Dealing
2014-10-17 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.